Artrya Limited (ASX:AYA)

Bernie brings a wealth of corporate experience to Artrya, including 37 years in private and ASX listed companies, spending most of that time in the role of Managing Director.

Bernie was Managing Director of the top ASX listed company Imdex Limited (Imdex) for 20 years, retiring in July 2020. During that time, Imdex’s revenue grew from approximately $20m per annum in Australia to more than of $270m per annum, generated from sales from over 100 countries. In that period, the market capitalization of Imdex grew from below $10m to over $600m, and now exceeds $800m; significantly more than of 60% of revenue was generated from outside Australia.

His vision is for Artrya to become the global standard in non-invasive AI and machine learning to diagnose and treat coronary artery disease. Coronary artery disease is the leading cause of death in the world and Artrya can have a positive impact on lowering this death rate. Artrya’s technology is truly disruptive in an area where technology advances in the past decades have been minimal.

Bernie holds a Bachelor of Business in Accounting, is a qualified Chartered Accountant, and is a fellow of the Australian Institute of Company Directors (FAICD).

Dr Jacque J. Sokolov is the Chairman and CEO of SSB, a US-based healthcare management and investment company with four strategic divisions: SSB Solutions, SSB Investment Funds, SSB Financial Services, and SSB Governmental Services. The company focuses on delivering value-based healthcare solutions across various sectors, having partnered with over 100 entities in the US. Dr Sokolov has been instrumental in transforming major healthcare corporations, including the turnaround of Humana Inc., the evolution of Hospira into a biosimilar manufacturing leader, and the merger of Summit Medical Group with CityMD.

He is also engaged with next-generation health platforms and genomic companies such as GlobalMed, Calviri, and Lucid Diagnostics. Recently, he has taken leadership roles at Artrya, contributing as Chairman of Artrya USA Inc. and serving on its global quality and compliance boards. Dr Sokolov began his career at Southern California Edison, restructuring one of the largest corporate ERISA health plans, achieving cost savings and improved healthcare outcomes.

Dr Sokolov holds an MD and BA from the University of Southern California, completing advanced training in internal medicine and cardiovascular imaging. He is active on various healthcare boards worldwide.

Ms Hill is an experienced non-executive director of ASX listed companies and has particular expertise at board level in both technology companies and also the biotech and medical devices sectors. In addition, she has experience of other listing exchanges including Nasdaq (US) and AIM (UK).

Kate previously spent over 20 years as an audit partner at Deloitte, serving both ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment.

She is currently the non-executive Chair of Seeing Machines Limited (LON:SEE) and a Director and Chair of the Audit and Risk Committee of Countplus Limited (ASX:CUP). She has been a non-executive Director and Chair of the Audit and Risk Committee of Elmo Software (ASX:ELO).

She is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.  She holds a BSc (Hons) in Mathematics and Statistics from the University of Bristol, UK.

Mr Regan is an experienced executive who has worked in a variety of Industries including ASX listed companies, Private Equity and Cooperatives.

He has worked in multi-disciplinary environments from supply chain and logistics to finance and trading and is skilled in business strategy, culture and human resources, information technology, cyber security, innovation, digital and artificial intelligence.

Mr Regan has a background of leading large information technology teams and delivering transformative change in large corporate environments.

He places a high value on combining education with practical experience having successfully completed post graduate placements at the University of Western Australia and Stanford, where he completed the Stanford Executive Program (SEP) focused on Business and Innovation.